ADT w raku prostaty 2022 – wybór czy konieczność? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 2, 2022
Słowa kluczowe:
rak prostaty, deprywacja androgenowa, nowoczesna hormonoterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Rak prostaty jest coraz częściej występującym nowotworem złośliwym. Terapia opiera się na postępowaniu miejscowym (chirurgia, radioterapia) i leczeniu systemowym (hormonoterapia, chemioterapia). Deprywacja androgenowa odgrywa kluczową rolę w leczeniu raka stercza. Różne kombinacje leków pozwalają na coraz dłuższy czas życia pacjentów. W artykule przedstawiono wybrane zagadnienia związane z nowymi możliwościami leczenia w różnych stadiach choroby.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Drobniak , A., & Malik , L. (2022). ADT w raku prostaty 2022 – wybór czy konieczność? . Medycyna Faktów , 15(3(56), 297-300. https://doi.org/10.24292/01.MF.0322.4
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Schulman CC , Irani J, Morote J. Deprivation therapy in prostate cancer: a European Expert Panel Review. Eur Urol Suppl. 2010; 9: 675-91.
2. Sternberg CN, Baskin-Bey ES, Watson M et al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol. 2013; 13: 58.
3. Merseburger AS, Hammerer P, Rozet F et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015; 33(8): 1079-85.
4. NCCN Guidelines. Prostate Cancer (access: 16.08.2022).
5. ESMO. CLINICAL PRACTICE GUIDELINES – PROSTATE CANCER (access: 16.08.2022).
6. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000; 56(6): 1021-4.
7. James ND, Sydes MR, Clarke NW et al. STAMPEDE Investigators Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-77.
8. Fizazi K, Foulon S, Carles J et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399(10336): 1695-707.
9. Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi, UroToday Home, ESMO 2021.
10. Attard G, Murphy L, Clarke NW et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399(10323): 447-60.
11. Cattrini C Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review Cancers 2022; 14(7): 1792.
12. De Galiza Barbosa F, Queiroz MA, Nunes RF et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020; 20: 23.
2. Sternberg CN, Baskin-Bey ES, Watson M et al. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer. BMC Urol. 2013; 13: 58.
3. Merseburger AS, Hammerer P, Rozet F et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2015; 33(8): 1079-85.
4. NCCN Guidelines. Prostate Cancer (access: 16.08.2022).
5. ESMO. CLINICAL PRACTICE GUIDELINES – PROSTATE CANCER (access: 16.08.2022).
6. Oefelein MG, Feng A, Scolieri MJ et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000; 56(6): 1021-4.
7. James ND, Sydes MR, Clarke NW et al. STAMPEDE Investigators Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163-77.
8. Fizazi K, Foulon S, Carles J et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022; 399(10336): 1695-707.
9. Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi, UroToday Home, ESMO 2021.
10. Attard G, Murphy L, Clarke NW et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022; 399(10323): 447-60.
11. Cattrini C Caffo O, De Giorgi U et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review Cancers 2022; 14(7): 1792.
12. De Galiza Barbosa F, Queiroz MA, Nunes RF et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020; 20: 23.